Therapeutic Solutions International Inc (TSOI)

[centsability4me]

Boris is much older than 2006
actually it might be around 1999.

link to TSI BORIS patent :

https://patents.google.com/patent/US20170143812

A scientist, Victor V. Lobanenkov, Ph.D., at NIH discovered the BORIS gene in 1999.

The NIH has a profile page of Dr. Lobanenkov which specifically covers ongoing research into BORIS as a senior investigator at NIH

https://irp.nih.gov/pi/victor-lobanenkov

Victor V. Lobanenkov, Ph.D.

Senior Investigator

Molecular Pathology Section NIAID/DIR

Dr. Lobanenkov received an M.A. in nuclear physics from the Institute of Physics in 1977 and a Ph.D. in experimental oncology from the Cancer Research Center, Moscow, in 1981. He was molecular carcinogenesis team leader in the All-Union Cancer Center of the former U.S.S.R. and a visiting scholar at the Royal Cancer Hospital, London, until 1990, where he discovered avian CTCF. He was invited to the Fred Hutchinson Cancer Research Center in Seattle as a foreign faculty-in-residence funded by NIH grants.

In 1999, he became chief of the Molecular Pathology Section in the Laboratory of Immunopathology; identified CTCF in Drosophila, mice, and man; and characterized the novel BORIS+CTCF gene family ,universally involved in epigenetic regulation of mammalian cellular and viral genomes. His section, which moved to the Laboratory of Immunogenetics in 2012, works to understand how genome-wide, CTCF/BORIS-binding sequences regulate different functions, including inter- and intra-chromosomal 3-D DNA-looping interactions, mono-allelic expression of imprinted and non-imprinted genes, X-chromosome inactivation, and regulation of stem/germ cell-specific promoters associated with targeted DNA demethylation.

Looking to the peer reviewed medical literature there have been over 2000 papers published:

https://www.ncbi.nlm.nih.gov/pubmed/?term=BORIS

-and isn’t it fascinating that our own Dr. Ichim has published alongside Dr. Lobanenkov as far back as 2006, and here we are in 2018 with a published patent on BORIS that is now available as treatment in Mexico.


Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites.

Ghochikyan A, Mkrtichyan M, Loukinov D, Mamikonyan G, Pack SD, Movsesyan N, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

J Immunol. 2007 Jan 1;178(1):566-73.

PMID: 17182597 Free PMC Article

Similar articles

Select item 18355444



2.

Selective apoptosis of breast cancer cells by siRNA targeting of BORIS.

Dougherty CJ, Ichim TE, Liu L, Reznik G, Min WP, Ghochikyan A, Agadjanyan MG, Reznik BN.

Biochem Biophys Res Commun. 2008 May 23;370(1):109-12. doi: 10.1016/j.bbrc.2008.03.040. Epub 2008 Mar 18.

PMID: 18355444

Similar articles

Select item 16741971



3.

Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant.

Loukinov D, Ghochikyan A, Mkrtichyan M, Ichim TE, Lobanenkov VV, Cribbs DH, Agadjanyan MG.

J Cell Biochem. 2006 Aug 1;98(5):1037-43.

PMID: 16741971

Similar articles

Select item 17972923



4.

DNA, but not protein vaccine based on mutated BORIS antigen significantly inhibits tumor growth and prolongs the survival of mice.

Mkrtichyan M, Ghochikyan A, Loukinov D, Davtyan H, Ichim TE, Cribbs DH, Lobanenkov VV, Agadjanyan MG.

Gene Ther. 2008 Jan;15(1):61-4. Epub 2007 Nov 1.

PMID: 17972923 Free PMC Article

As I dig further, I see the name below “Reznik BN” who has also published with Dr. Ichim and Dr. Lobanenkov. I thought I had seen that name before in a press release :

http://therapeuticsolutionsint.com/?page_id=142

-and found this quote from Dr. Reznik “It is a pleasure to work with the team at Emvolio on clinical translation of this exciting immunotherapeutic approach to cancer,” said Boris Reznik, Chairman and CEO of Biorasi, Inc. “As a Contract Research Organization (CRO) that loves to assist promising companies operating in the area of the Cutting Edge of Medicine, we are pleased that our collaboration has culminated into this regulatory filing.”

Apparently BioRASI is a CRO http://www.biorasi.com fortune 500
company that assisted them in the StemVacs IND filed last year.

More to follow ,
-Cents